deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT00368082

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (TGF-beta)

Administration of TGF-b Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma

Sponsor: Baylor College of Medicine

Updated 19 times since 2017 Last updated: Oct 30, 2025 Started: Apr 30, 2006 Primary completion: Sep 30, 2013 Completion: Jul 31, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hodgkin's Disease and Lymphoma and is currently ongoing. Baylor College of Medicine leads this study, which shows 19 recorded versions since 2006 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Nov 2019 · 12 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Oct 2021 · 7 months · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Jan 2023 · 12 months · monthly snapshot~Jan 2023 – ~Dec 2023 · 11 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Nov 2025 · 11 months · monthly snapshot~Nov 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded
  1. Nov 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Dec 2024 — Nov 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

Show 14 earlier versions
  1. Jan 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE1

  3. Oct 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Mar 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Nov 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  9. Nov 2018 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  10. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

  11. Nov 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  12. Sep 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE1

  13. Feb 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE1

  14. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baylor College of Medicine
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • The Methodist Hospital Research Institute
Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations